Biogen Plunges as Multiple Sclerosis Drug Fails in Trial

  • Stock falls most since July 2015 on mid-stage trial miss
  • Patients didn’t do significantly better than those on placebo

Biogen Inc. plunged the most in almost a year after an experimental drug for multiple sclerosis that investors and patients had hoped might alter the course of the neurological disease failed in a mid-stage trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.